Piper Sandler Initiates Coverage on TransMedics Group (NASDAQ:TMDX)

Research analysts at Piper Sandler began coverage on shares of TransMedics Group (NASDAQ:TMDX) in a report released on Thursday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $95.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 28.17% from the stock’s current price.

A number of other analysts have also recently issued reports on TMDX. Oppenheimer increased their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

TransMedics Group Price Performance

TransMedics Group stock opened at $74.12 on Thursday. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -96.26 and a beta of 2.01. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $99.63. The firm has a 50 day moving average price of $83.45 and a 200 day moving average price of $70.01.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. During the same period last year, the company posted ($0.21) EPS. The business’s quarterly revenue was up 158.6% on a year-over-year basis. Sell-side analysts predict that TransMedics Group will post -0.22 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 736 shares of TransMedics Group stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares in the company, valued at $1,295,043.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Tamer I. Khayal sold 736 shares of TransMedics Group stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the transaction, the insider now owns 14,375 shares in the company, valued at approximately $1,295,043.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now owns 14,375 shares in the company, valued at $1,155,893.75. The disclosure for this sale can be found here. Insiders sold a total of 92,949 shares of company stock worth $7,710,719 in the last 90 days. 6.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. grew its holdings in shares of TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after purchasing an additional 355,755 shares during the last quarter. Eagle Health Investments LP boosted its position in TransMedics Group by 78.5% during the 3rd quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock valued at $22,678,000 after purchasing an additional 182,173 shares during the period. Qube Research & Technologies Ltd grew its stake in TransMedics Group by 31.2% during the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock worth $4,624,000 after buying an additional 20,081 shares during the last quarter. Sei Investments Co. increased its position in TransMedics Group by 17.8% in the third quarter. Sei Investments Co. now owns 386,082 shares of the company’s stock worth $21,139,000 after buying an additional 58,269 shares during the period. Finally, Blair William & Co. IL bought a new stake in TransMedics Group in the third quarter valued at $358,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.